Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.

IPF is characterized by the accumulation of scar tissue that stiffens the lungs and makes it difficult for patients to breathe and get sufficient oxygen into their blood. Though the causes of IPF remain unclear, age is a significant risk factor: the disease is estimated to affect 1 in 200 US adults over the age of 70.

The scars are thought to arise from a runaway wound healing process in which lung cells deposit excessive amounts of collagen into their surroundings, stiffening the lung tissue and activating highly contractile cells called myofibroblasts. These myofibroblasts produce still more collagen fibers and stiffen the tissue even further.

Lung fibrosis resolution is thought to involve degradation of excessive collagen, removal of myofibroblasts, and regeneration of normal lung tissue by stem cells. However, the mechanisms underlying the reversal of lung fibrosis remain poorly understood."

Yong Zhou, Associate Professor, Department of Medicine, University of Alabama at Birmingham

Zhou and colleagues, including first author Jing Qu, discovered that the levels of a protein called MDM4 are elevated in the myofibroblasts of IPF patients and are also increased in aged mice with pulmonary fibrosis. The researchers found that the protein is produced in response to the increased stiffness associated with IPF.

MDM4 is known to inhibit a key transcription factor called p53. Zhou and colleagues found that reducing MDM4 levels activates a p53-dependent genetic program that makes myofibroblasts more likely to die and be removed from fibrotic tissues. Removing the Mdm4 gene from collagen-producing fibroblasts and myofibroblasts promoted the resolution of lung fibrosis in aged mice.

The researchers also found that treating mice with chebulic acid, a naturally occurring compound that removes the chemical cross-links between collagen fibers, could soften fibrotic tissue, increase enzyme-mediated collagen degradation, and reduce MDM4 levels, again resulting in the resolution of lung fibrosis.

"Targeting the mechanical properties of the lung microenvironment represents a promising strategy for anti-fibrotic therapy," says Zhou. "Our study identifies MDM4 as a mechanosensitive protein and a novel molecular target in pulmonary fibrosis and highlights the therapeutic potential of targeting collagen cross-linking to reverse persistent lung fibrosis associated with aging."

Journal reference:

Qu, J., et al. (2021) Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice. Journal of Experimental Medicine.


  1. maria alesse maria alesse United States says:

    could the use of chebulic acid be beneficial in dogs with Idiopathic Lung Disease?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify ORF6 protein as key to SARS-CoV-2 immune evasion